/ INVESTING, STOCKS, CONSUMER-STAPLES, HEALTHCARE, VALUATION

Protein Doritos and the Ozempic Grocery Panic: How Weight-Loss Drugs Broke Big Food's Brain (And Created a Bargain Stock)

You know a consumer trend has officially crossed from medical curiosity into full-blown corporate panic when executives at Frito-Lay start trying to turn nacho cheese tortilla chips into health food.

That is not a parody headline. With roughly 11% to 18% of American adults now taking GLP-1 weight-loss medications like Ozempic, Wegovy, and Zepbound—and oral pill versions expanding access even faster—PepsiCo (PEP) has spent the past year re-engineering its snack portfolio, rolling out protein- and fiber-fortified versions of Doritos and SunChips, stripping artificial dyes out of its “Simply NKD” lines, and buying up perimeter-of-the-store brands like Sabra and Siete.

Across the aisle, Mondelez (MDLZ) is busy shrinking Oreos and Chips Ahoy! into tiny “portion-controlled” 100-calorie snack packs so consumers whose appetites have been chemically muted don’t abandon cookies altogether.

It is easy to poke fun at the idea of a “high-protein Dorito.” For seventy years, Big Food’s entire business model relied on food scientists engineering the exact “bliss point” of salt, sugar, and fat to trigger mindless 11:00 PM couch munching. Then Eli Lilly (LLY) and Novo Nordisk (NVO) invented a molecule that turns off the human brain’s craving switch—and suddenly, hundreds of billions of dollars in consumer-staples market cap are scrambling for a new identity.

Yet while Wall Street has been obsessed with which junk-food giants might lose volume, the market has created a bizarre valuation anomaly in the one grocery category GLP-1 doctors actually prescribe.


The Craving Crash: From Salty Chips to Modelo Beer

To understand why consumer-packaged-goods (CPG) boardrooms are sweating, look at what happens to a household’s grocery receipt the moment someone starts a GLP-1 prescription.

It isn’t just that overall calorie intake drops by 20% to 30%. The composition of the shopping cart changes overnight. Impulse purchases of savory chips and sweet baked goods fall off a cliff. Even more surprising has been the collateral damage in the alcohol aisle.

Because GLP-1 receptor agonists dampen dopamine spikes in the brain’s reward center, roughly 45% of GLP-1 users report drinking significantly less alcohol. That neurological side effect—compounded by younger consumers already moderating their drinking—has put a structural ceiling on beverage alcohol volumes, compressing Constellation Brands (STZ), the powerhouse behind Modelo Especial and Corona, down to a multi-year low multiple of roughly 12.0x forward earnings.


The Valuation Paradox: Why Is the #1 Protein Shake Trading at 8x Earnings?

Now ask any endocrinologist or obesity specialist what they tell every single patient starting Wegovy or Zepbound. Their number-one rule is simple: eat 100+ grams of protein a day and lift weights.

When you lose weight rapidly on a GLP-1 drug without consuming enough protein, up to a third of the weight you lose comes from lean muscle mass (sarcopenia) rather than fat. And when your appetite is so suppressed that looking at a chicken breast makes you feel full, the easiest way to hit your daily protein target is to drink a 30-gram ready-to-drink (RTD) protein shake for breakfast.

That biological reality should make BellRing Brands (BRBR)—the parent company of Premier Protein, the dominant #1 ready-to-drink protein shake sold in Costco, Walmart, and Sam’s Club, as well as Dymatize protein powders—the undisputed darling of the consumer staples sector.

Instead, look at how the stock market is pricing these four grocery-aisle players right now:

Company Ticker Core Brands FY26 Revenue Context Forward P/E The GLP-1 Reality Check
BellRing Brands BRBR Premier Protein, Dymatize $2.34B–$2.38B guide ~7.5x–8.0x Deep Value Winner: #1 RTD protein shake crushed by temporary whey costs & inventory noise
Constellation Brands STZ Modelo Especial, Corona Core beer still profitable ~12.0x Cheap for a Reason: 45% of GLP-1 users cut alcohol; volume growth is structurally capped
PepsiCo PEP Doritos, Lay’s, Pepsi, Gatorade Re-working North America snacks ~16.5x Dividend Aristocrat in Transition: ~3.4% yield pays you while it pivots to “functional” snacks
Mondelez MDLZ Oreo, Cadbury, Ritz >70% international sales ~19.0x Geographic Buffer: Emerging-market chocolate sales shield it from U.S. Ozempic headwinds for now

Wait a second. Why is Mondelez (MDLZ)—a company that literally sells sugar cookies and chocolate bars—trading at 19x forward earnings, while BellRing Brands (BRBR)—a company generating $2.35 billion in annual sales selling the exact 30-gram protein shakes GLP-1 patients chug every morning—has been beaten down to roughly 7.5x to 8.0x forward earnings (around $10.55 a share)?

Because short-term Wall Street algorithms hate supply-chain messiness. Over the past year, BellRing got hit by a perfect storm of surging liquid whey protein input costs, fierce shelf competition from Coca-Cola’s (KO) ultra-filtered Fairlife / Core Power shakes, and lumpy club-store inventory destocking charges at Costco (COST) and Sam’s Club. Hedge funds dumped the stock indiscriminately, compressing a secular category leader to a single-digit distressed multiple—ignoring the fact that BellRing’s asset-light, co-manufactured business model converts the vast majority of its earnings straight into free cash flow that management is now using to cannibalize its own depressed shares via buybacks.


How to Trade the New Grocery Cart

When a permanent medical shift rewires how 30 million Americans eat and drink, don’t pay a premium multiple for companies trying to glue a “healthy” label onto junk food.

  • Buy the Distressed Category Leader (BRBR): At roughly 7.5x to 8.0x forward earnings, BellRing Brands (BRBR) is priced as if Americans are going to stop drinking Premier Protein shakes tomorrow. In reality, household penetration for RTD protein shakes is still expanding, GLP-1 doctors act as an unpaid national salesforce for 30-gram shakes, and whey input-cost inflation is cyclical. When club-store inventory normalizes, a re-rating from 8x back toward a modest 14x consumer-staples multiple offers 70%+ upside.
  • Prefer International Sweet Exposure (MDLZ) Over Domestic Salty Snacks (PEP): If you want a defensive blue-chip staple, Mondelez (MDLZ) has a natural moat that PepsiCo’s Frito-Lay unit lacks: more than 70% of Mondelez’s revenue comes from outside the United States, including fast-growing emerging markets where $1,000-a-month weight-loss drugs won’t dent Oreo or Cadbury volumes for years.
  • Don’t Fall for the Alcohol “Value Trap” (STZ): Constellation Brands (STZ) looks tempting on a screen at 12x earnings, and Modelo remains a fantastic beer brand. However, when both Gen Z cultural habits and GLP-1 pharmacology are pulling in the exact same anti-alcohol direction, fighting two secular headwinds at once is a tough way to make money.

You don’t have to eat Protein Doritos to profit from the Ozempic grocery makeover. Just buy the protein shake company that Wall Street threw in the clearance bin.